Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 9, 2005, Pages 1573-1585

  Kaplan, Susan S ^a   Hicks, Charles B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Lopinavir ritonavir (Kaletra ); Protease inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; CHOLESTEROL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; EMTRICITABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMIVUDINE; LIPID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ALLERGIC REACTION; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY SKIN; FATTY LIVER; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IC 50; INCIDENCE; LIPOATROPHY; LIPODYSTROPHY; LIVER DYSFUNCTION; NAUSEA; NONHUMAN; PANCREATITIS; PHARMACODYNAMICS; REVIEW; TASTE DISORDER; VIRUS INFECTION; VOMITING;

ADMINISTRATION, ORAL; CD4 LYMPHOCYTE COUNT; CYTOCHROME P-450 CYP3A; DOSAGE FORMS; DRUG APPROVAL; DRUG COMBINATIONS; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PYRIMIDINONES; RANDOMIZED CONTROLLED TRIALS; RITONAVIR; VIRAL LOAD;

EID: 23644433035     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.9.1573     Document Type: Review

References (86)

1. UNAIDS EXECUTIVE SUMMARY: 2004 Report on the Global Aids Epidemic. June, 2004.
2. PALELLA FJ, DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338(13):853-860.
3. HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. (1997) 337(11):725-733.
4. PALELLA FJ, DELORIA-KNOLL M, CHMIEL JS et al.: Survival benefit of initiating antirerroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. (2002) 138(8):620-626.
5. PANEL ON CLINICAL PRACTICES FOR TREATMENT OF HIV INFECTION: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 7 April, 2005.
6. CONDRA JH, PETROPOULOS CJ, ZIERMANN R et al.: Drug resistance and predicted virologic responses to human immunodeficiency virus Type 1 protease inhibitor therapy. J. Infect. Dis. (2000) 182(3):758-765.
7. BERTZ R, LAM W, BRUN S et al.: Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV+ subjects. In: Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, 26-29 September, 1999 (Abstr. 0327).
8. KUMAR GN, DYKSTRA J, ROBERTS EM et al.: Potent inhibition of the cytochrome P450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. (1999) 27(8):902-908.
9. DEBOUCK C: The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. and Human Retrovir. (1992) 8(2):153-164.
10. MOLLA A, KORNEYEVA M, GAO Q et al.: Ordered accumulation of mutations in HIV prorease confers resistance to ritonavir. Nat. Med. (1996) 2(7):760-766.
11. SHAM HL, KEMPF DJ, MOLLA A et al.: ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. (1998) 42(12):3218-3224.
12. KUMAR GN, RODRIGUES AD, BUKO AM, DENISSEN JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. (1996) 277(1):423-431.
13. KEMPF DJ, MARSH KC, KUMAR G et al.: Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. (1997) 41(3):654-660.
14. MARSH K, MCDONALD E, SHAM H, KEMPF D, NORBECK D: Enhancement of ABT-378 pharmacokinetics when administered in combination with ritonavir. Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, US (1 - 5 February, 1998) (Abstr. 210).
15. LAL RA, HSU A, CHEN P et al.: Single dose pharmacokinetics of ABT-378 in combination with ritonavir. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (28 September - 1 October, 1997) (Abstr. I-194).
16. LAL RA, HSU A, GRANNEMAN GR et al.: Multiple dose safety, tolerability, and pharmacokinetics of ABT-378 in combination with ritonavir. Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, USA, 1 - 5 February, 1998 (Abstr. 647).
17. MURPHY RL, BRUN S, HICKS C et al.: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 15(1):F1-F9.
18. CROMMENTUYN KM, MULDER JW, MAIRUHU AT et al.: The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1 infected patients. Antivir. Ther. (2004) 9(5):779-785.
19. BERTZ R, RENZ C, FOIT C et al.: Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100mg BID) in HIV-subjects when taken with food. Proceedings of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands 2 - 4 April, 2001 (Abstr. 3,10).
20. GUSTAVSON L, LAM W, BERTZ R et al.: Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir (ABT-378/r) in healthy subjects. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada 17 - 20 September, 2000 (Abstr. 1659).
21. BENSON CA, DEEKS SG, BRUN SC et al.: Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus Type 1-infected protease inhibitor-experienced patients. J. Infect. Dis. (2002) 185(5):599-607.
22. ERON JJ, FEINBERG J, KESSLER HA et al.: Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J. Infect. Dis. (2004) 189(2):265-272.
23. CHIU Y-L, FOIT C, GATHE J et al.: Multiple-dose pharmacokinetics and initial antiviral effect of once daily lopinavir/ritonavir (LPV/r) in combination with tenofovir (TDF) and emtricitabine (FTC) in HIV-infected antirecroviral-naive subjects (Study 418). Proceedings of the Second IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13 - 16 July, 2003 (Abstr. 839).
24. GATHE J, PODZAMCZER D, JOHNSON M et al.: Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8 - 11 February, 2004 (Abstr. 570).
25. VERWEEL G, VAN DER LEE M, BURGER D, DE GROOT R: 6-month follow-up of once-daily lopinavir/ritonavir in HIV-1-infected children. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 22 - 25 February, 2005 (Abstr. 769).
26. HSU A, ISAACSON J, BRUN S et al.: Pharmacokinetics-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2003) 47(1):350-359.
27. BERTZ R, CHIU Y-L, NAYLOR C, LUFF K, BRUN SC: Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14 November - 18, 2004 (Abstr. 201).
28. HSU A, BERTZ R, RENZ C et al.: Assessment of the pharmacokinetic interaction between lopinavir/ritonavir (ABT-378/r) and nevirapine (NVP) in HIV-infected pediatric subjects. AIDS (2000) 14(Suppl. 4):S100.
29. SAEZ-LLORENS X, VIOLARI A, DEETZ CO et al.: Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. (2003) 22(3):216-223.
30. MOLLA A, VASAVANONDA S, KUMAR G et al.: Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology (1998) 250(2):255-262.
31. BOFFITO M, HOGGARD PG, LINDUP WE et al.: Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther. Drug Monit. (2004) 26(1):35-39.
32. HICKMAN D, VASAVANONDA S, NEQUIST G et al.: Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob. Agents Chemother. (2004) 48(8):2911-2917.
33. HSU A, BERTZ R, HICKMAN D et al.: Assessment of plasma protein binding of lopinavir (LPV) and ritonavir (RTV) between in vitro and ex vivo experiments and between HIV-infected patients and HIV-negative healthy volunteers. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, USA, 2001.
34. GHOSN J, CHAIX ML, GP et al.: Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 18(14):1958-1961.
35. LAUNAY O, TOD M, LOUCHAHI K et al.: Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob. Agents Chemother. (2004) 48(2):632-634.
36. ISAAC A, TAYLOR S, CANE P et al.: Lopinavir/ritonavir combined with twice-daily 400mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J. Antimicrob. Chemother. (2004) 54(2):498-502.
37. YILMAZ A, STAHLE L, HAGBERG L et al.: Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand. J. Infect. Dis. (2004) 36(11-12):823-828.
38. CAPPARELLI EV, HOLLAND D, OKAMOTO C et al.: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS (2005) 19(9):949-952.
39. VAN DEN BRANDE G, MARQUIEBECK J, CAPPARELLI E et al.: Kaletra independently reduces HIV replication in cerebrospinal fluid. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA 22 - 25 February, 2005 (Abstr. 403).
40. SOLAS C, LAFEUILLADE A, HALFON P et al.: Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2003) 47(1):238-243.
41. KUMAR GN, JAYANTI V, LEE RD et al.: In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab. Dispos. (1999) 27(1):86-91.
42. KUMAR GN, JAYANTI VK, JOHNSON MK et al.: Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharmaceut. Res. (2004) 21(9):1622-1630.
43. HICKS C, KING MS, GULICK RM et al.: Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year followl-up study. AIDS (2004) 18(5):775-779.
44. HICKS C, DA SILVA B, BENSON C et al.: Extensive resistance testing during 5 years of lopinavir/ritonavir treatment in antiretroviral-naive HIV infected patients: Results from study M97-720. Proceedings of the XV International AIDS Conference. Bangkok, Thailand (11 - 16 July, 2004) (Abstr. WeOrB1291).
45. BENSON C, DA SILVA B, MCMILLAN F et al.: 300-week follow-up of lopinavir/ritonavir (LPV/r)-based therapy in antiretroviral (ARV)-naive, HIV infected patients. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA 30 October - 2 November, 2004 (Abstr. H-568).
46. GULICK RM, DA SILVA B, MCMILLAN F et al.: Lopinavir/ritonavir (LPV/r)-based therapy in antiretroviral (ARV)-naive, HIV-infected patients: 6-year follow-up of Study 720. Proceedings of the Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14 - 18 November, 2004 (Abstr. P28).
47. WALMSLEY S, BERNSTEIN B, KING M et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. (2002) 346(26):2039-2046.
48. KING M, BERNSTEIN B, CERNOHOUS P et al.: Impact of baseline CD4 cell count and viral load on durability of virologic response through 96 weeks for lopinavir/ritonavir and nelfinavir in a Phase III clinical trial. Proceedings of the 9th Confernce on Retroviruses and Opportunistic Infections. Seattle, Washington, USA, 24 - 28 February, 2002 (Abstr. 470-M).
49. KING MS, BERNSTEIN BM, WALMSLEY SL et al.: Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J. Infect. Dis. (2004) 190(2):280-284.
50. KEMPF DJ, KING MS, BERNSTEIN B et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. (2004) 189(1):51-60.
51. HICKS C, BRUN S, KING M et al.: Kaletra (lopinavir/ritonavir) therapy in single protease inhibitor-experienced patients: 144 week follow up. Proceedings of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece. (Abstr. 220).
52. POLLARD RB, THOMPSON MA, HICKS CB et al.: Phase III comparison of lopinavir/ritonavir versus investigator-selected protease inhibitors in single PI-experienced, NNRTI-naive patients: 48-week result of study M98-888. Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14 - 18 November, 2004 (Abstr. PL3.2).
53. CLUMECK N, BRUN S, SYLTE J et al.: Kaletra (ABT-378/r) and efavirenz: one-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients. Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, UK, 4 - 8 February; 2001 (Abstr. 525).
54. KEMPF DJ, ISAACSON JD, KING MS et al.: Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. (2002) 7(3):165-174.
55. CAHN P, RENZ C, SAEZ-LLORENS X et al.: Kaletra (ABT-378/ritonavir) in HIV-infected children at 72 weeks. Proceedings of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 8 - 11, 2001 (Abstr. 779).
56. LAFEUILLADE A, DUPON M, LIVROZET J-M et al.: Efficacy and tolerance of lopinavir/ritonavir in clinical practice: an observational prospective cohort of 1278 patients. Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14 - 18 November, 2004 (Abstr. 140).
57. BURGOS A, CABRERO E, GROUP ATVS: Response to lopinavir/ritonavir-based HAART and its dependence on prior ARV experience: 24-week interim analysis (VIHvir+ Study). Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 14 - 18, 2004 (Abstr. 299).
58. YOULE M, GERSTOFT J, FOX Z et al.: The final week 48 analysis of a Phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): the MaxCmin2 trial. Proceedings of the 9th European AIDS Conference. Warsaw, Poland, 25 - 29 October, 2003 (Abstr. F11/3).
59. JOHNSON M, DEJESUS E, GIRINSZTEJN B et al.: Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV-infected patients with multiple virologic failures: 96-week results from a randomized, open-label trial, BMS A1424045. Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14 - 18 November, 2004 (Abstr. PL14.4).
60. ELSTON RC, YATES P, TISDALE M et al.: GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. MoOrB1055).
61. DEJESUS E, LAMARCA A, SENSION M, BELTRAN C, YENI P: The Context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 10 - 14 February, 2003 (Abstr. 178).
62. COOPER D, HICKS C, CAHN P et al.: 24-week RESIST study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 22 - 25 February, 2005 (Abstr, 560).
63. NOLAN D: Metabolic complications associated with HIV protease inhibitor therapy. Drugs (2003) 63(23):2555-2574.
64. SULKOWSKI MS: Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver Dis. (2003) 23(2):183-194.
65. SULKOWSKI MS, MEHTA SH, CHAISSON RE, THOMAS DL, MOORE RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 18(17):2277-2284.
66. DA SILVA B, KING M, CERNOHOUS P, BRUN S: Lopinavir/ritonavir (LPV/r) safety, tolerability, and efficacy in HIV patients co-infected with hepatitis C and/or hepatitis B: review of clinical trials. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. MoPeB3285).
67. MALLAL SA, JOHN M, MOORE CB, JAMES IR, MCKINNON EJ: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS (2000) 14(10):1309-1316.
68. MARTINEZ E, DOMINGO P, GALINDO MJ et al.: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir/ritonavir. Clin. Infect. Dis. (2004) 38(7):1017-1023.
69. LEE GA, SENEVIRATNE T, NOOR MA et al.: Metabolic effects of lopinavir/ritonavir (Kaletra) in healthy HIV-seronegative men. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 10 - 14 February, 2003 (Absts. 748).
70. CRANE H, VAN ROMPAEY S, KITAHATA M: The association between increasing blood pressure and use of NNRTI and lopinavir/ritonavir. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA, 22 - 25 February; 2005) (Abstr. 873).
71. BHIVA WRITING COMMITTEE ON BEHALF OF THE BHIVA EXECUTIVE COMMITTEE: British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. July, 2003.
72. WORKING GROUP ON ANTIRETROVIRAL THERAPY AND MEDICAL MANAGEMENT OF HIV-INFECTED CHILDREN: Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 24 March, 2005.
73. AIDS STUDY GROUP (GESIDE) AND THE CLINICAL ADVISORY COMMITTEE (CAC) OF THE NATIONAL AIDS PLAN (PNS) OF THE MINISTRY OF HEALTH (MSC): Recommendations from GESIDA/National AIDS plan on antiretroviral therapy in adult patients infected by the human immunodeficiency virus. October, 2004.
74. STEK A, MIROCHNICK M, CAPPARELLI E et al.: Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. LbOrB08).
75. KING M, NORTON M, BRUN S et al.: Prevalence of multiple prorease mutations at positions 33, 82, 84 and 90 among PI-experienced patients and the effect on virologic response to lopinavir/ritonavir-based regimens. Proceedings of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14 - 18 November, 2004 (Abstr. P100).
76. NGO VAN P, COHEN-CODAR I, BOER F et al.: Study of the initial response to Kaletra in HIV treatment-experienced patients: the ATU pre-registrational cohort in France. Proceedings of the 8th European Conference on Clinical Aspects and Treatment of HIV infection. Athens, Greece, 28 - 31 October, 2001 (Abstr. 236).
77. KEMPF DJ, ISAACSON JD, KING MS et al.: Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. (2001) 75(16):7462-7469.
78. DA SILVA B, CERNOHOUS P, KING M et al.: SOKRATES: Prospective evaluation of resistance in protease during lopinavir/ritonavir development. Proceedings of the Second IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13 - 16 July, 2003 (Abstr. 779).
79. MOLINA JM, GATHE J, LIM PL et al.: Comprehensive resistance testing in antiretroviral-naive patients treated with once-daily lopinavir/ritonavir plus tenofovir DF and emtricitabine: 48-week results from study 418. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. WePeB5701).
80. CONRADIE F, SANNE I, VENTER W, ERON J: Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS (2004) 18(7):1084-1085.
81. FRIEND J, PARKIN N, LIEGLER T, MARTIN JN, DEEKS SG: Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS (2004) 18(14):1965-1970.
82. MO H, KING MS, KING K et al.: Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus Type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. (2005) 79(6):3329-3338.
83. GATHE JR. JC, WASHINGTON MY, MAYBERRY C, PIOT D, NEMECEK J: IMANI-1 TC3WP single drug HAART-proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV+ ARV-naive patients - interim analysis of subjects completing final 48 week data. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. MoOrB1057).
84. ARRIBAS JR, PULIDO F, LORENZO A et al.: Simplification to lopinavir/r single-drug HAART: 24 weeks results of a randomized, controlled, open label, pilot clinical trial (OK study). Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. TuPeB4486).
85. PIERONE G, MIERAS J, FONTAINE L et al.: Simplification to lopinavir/ritonavir monotherapy from NNRTI-based HAART in HIV-infected patients with complete viral suppression. Proceedings of the XV International AIDS Conference. Bangkok, Thailand, 11 - 16 July, 2004 (Abstr. TuPeB4595).
86. RAFFI F, ALLAVENA C, DELFRAISSY JF et al.: 48-week final results of lopinavir/r (LPV/r)-efavirenz (EFV) combination (BIKS study). Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October - 2 November, 2004 (Abstr. H-569).